Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05288855 · ClinicalTrials.gov registry record · Phase 3

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

A Phase 3 study, sponsored by Aurinia Pharmaceuticals.

Terminated
Registry status
Phase 3
Development phase
9
Enrollment target

NCT05288855: Clinical Trial Phase 3 study, sponsored by Aurinia Pharmaceuticals.

NCT05288855 is a Phase 3 study that was terminated before completion, run by Aurinia Pharmaceuticals. The registered enrollment target is 9 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05288855, a Phase 3 study, was terminated before completion, sponsored by Aurinia Pharmaceuticals.

TERMINATED
Registry status
Phase 3
Development phase
9 participants
Enrollment target

Study Summary

The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescent and pediatric subjects with active lupus nephritis (LN).

Primary Outcome

Renal response defined as UPCR ≤0.5 mg/mg, eGFR ≥60 mL/min/1.73 m2 or no decrease from baseline of \>20%, no rescue medication and no steroid use \>10 mg/day for ≥3 consecutive days or for ≥7 days in total between week 16 to 24

Interventions

  • DRUG Placebo Oral Capsule
  • DRUG Voclosporin

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2023-10-10
Est. Completion 2025-07-03
Phase Phase 3
Aurinia Pharmaceuticals

13 total trials

Why NCT05288855 stopped before completion

NCT05288855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Capsule is the first listed.

NCT05288855 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05288855 about?

NCT05288855 is a clinical study titled "Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis". The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescent and pediatric subjects with active lupus nephritis (LN).

What is the current status of trial NCT05288855?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2023-10-10. Estimated completion is 2025-07-03.

What interventions are being tested in trial NCT05288855?

The interventions under investigation include: Placebo Oral Capsule (DRUG), Voclosporin (DRUG).

Who is sponsoring clinical trial NCT05288855?

This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05288855's enrollment target sits among peer trials

9 1992nd of 2000 higher than 8 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05288855, the US trial registry maintained by the National Library of Medicine. NCT05288855 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.